China Universal Asset Management Co. Ltd. Purchases 22,580 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

China Universal Asset Management Co. Ltd. raised its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 630.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 26,160 shares of the biopharmaceutical company's stock after buying an additional 22,580 shares during the quarter. Alnylam Pharmaceuticals comprises 1.0% of China Universal Asset Management Co. Ltd.'s investment portfolio, making the stock its 26th largest position. China Universal Asset Management Co. Ltd.'s holdings in Alnylam Pharmaceuticals were worth $5,007,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in the business. Harbor Capital Advisors Inc. boosted its position in shares of Alnylam Pharmaceuticals by 1.8% during the fourth quarter. Harbor Capital Advisors Inc. now owns 2,938 shares of the biopharmaceutical company's stock valued at $562,000 after purchasing an additional 51 shares in the last quarter. Captrust Financial Advisors raised its stake in shares of Alnylam Pharmaceuticals by 4.3% in the second quarter. Captrust Financial Advisors now owns 1,285 shares of the biopharmaceutical company's stock worth $187,000 after purchasing an additional 53 shares during the last quarter. EP Wealth Advisors LLC increased its position in Alnylam Pharmaceuticals by 6.4% during the third quarter. EP Wealth Advisors LLC now owns 1,177 shares of the biopharmaceutical company's stock valued at $208,000 after acquiring an additional 71 shares during the last quarter. CIBC Asset Management Inc increased its position in Alnylam Pharmaceuticals by 2.0% during the first quarter. CIBC Asset Management Inc now owns 4,191 shares of the biopharmaceutical company's stock valued at $840,000 after acquiring an additional 84 shares during the last quarter. Finally, Oppenheimer & Co. Inc. increased its position in Alnylam Pharmaceuticals by 2.1% during the third quarter. Oppenheimer & Co. Inc. now owns 4,519 shares of the biopharmaceutical company's stock valued at $800,000 after acquiring an additional 93 shares during the last quarter. 92.97% of the stock is currently owned by institutional investors.

Alnylam Pharmaceuticals Stock Up 0.4 %

NASDAQ:ALNY traded up $0.65 during midday trading on Thursday, hitting $151.48. The stock had a trading volume of 531,882 shares, compared to its average volume of 844,235. The company has a market capitalization of $19.08 billion, a price-to-earnings ratio of -42.55 and a beta of 0.39. The stock has a 50-day moving average of $156.85 and a 200 day moving average of $168.74. Alnylam Pharmaceuticals, Inc. has a one year low of $143.52 and a one year high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last announced its earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.20) by $0.10. The company had revenue of $439.72 million for the quarter, compared to the consensus estimate of $439.38 million. The firm's revenue was up 31.2% compared to the same quarter last year. During the same period last year, the business posted ($1.68) EPS. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -4.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms recently commented on ALNY. William Blair reiterated an "outperform" rating on shares of Alnylam Pharmaceuticals in a research report on Monday, January 8th. Cantor Fitzgerald reissued a "neutral" rating and set a $165.00 price target on shares of Alnylam Pharmaceuticals in a report on Tuesday, February 20th. Needham & Company LLC reissued a "buy" rating and set a $200.00 price target on shares of Alnylam Pharmaceuticals in a report on Thursday, February 15th. Chardan Capital cut their price target on Alnylam Pharmaceuticals from $250.00 to $225.00 and set a "buy" rating for the company in a report on Friday, February 16th. Finally, Wells Fargo & Company cut their price target on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an "equal weight" rating for the company in a report on Friday, February 16th. Eight investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $216.12.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.